Evidence map›Paper›PMID 26647976›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2016

Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats.

Kiri L Wills, Gavin N Petrie, Geneva Millett, Cheryl L Limebeer, Erin M Rock, Micah J Niphakis, Benjamin F Cravatt, Linda A Parker

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Kiri L WillsCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.
Gavin N PetrieCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.
Geneva MillettCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.
Cheryl L LimebeerCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.
Erin M RockCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.
Micah J NiphakisSkaggs Institute for Chemical Biology, Department of Chemical Physiology, Scripps Research Institute, La Jolla, CA, USA.
Benjamin F CravattSkaggs Institute for Chemical Biology, Department of Chemical Physiology, Scripps Research Institute, La Jolla, CA, USA.
Linda A ParkerCollaborative Neuroscience Program, Department of Psychology, University of Guelph, Guelph, ON, Canada.ORCID 0000-0002-3494-9754
University of Guelph · CAScripps Research Institute · US

Funding

STRUCTURAL STUDIES OF FAAHP01DA017259 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI STEVENS, RAYMOND C · 2004 to 2013
$10.6M
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENTR01DA033760 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, SCAMPAVIA, LOUIS DANIEL · 2012 to 2021
$5.1M
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)R01DA032933 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, LICHTMAN, ARON H · 2012 to 2014
$1.5M
CIHR 137122NIDA NIH HHS P01 DA017259NIDA NIH HHS R01 DA032933NIDA NIH HHS R01 DA033760
6 · The paper itself

Abstract

Both CB1 receptor antagonism and agonism, in particular by 2-arachidonyl glycerol (2-AG), have been shown to reduce somatic symptoms of morphine withdrawal (MWD). Here we evaluated the effects of both systemic pretreatment with the monoacylglycerol lipase (MAGL) inhibitor MJN110 (which selectively elevates 2-AG) and central administration of both MJN110 and the CB1 antagonist (AM251) on the affective properties of MWD. Acute MWD induced place aversion occurs when naloxone is administered 24 h following a single exposure to a high dose of morphine. Systemic pretreatment with the MAGL inhibitor, MJN110, prevented the aversive effects of acute MWD by a CB1 receptor-dependent mechanism. Furthermore, in a double dissociation, AM251 infusions into the central amygdala, but MJN110 infusions into the basolateral amygdala, interfered with the naloxone-precipitated MWD induced place aversion. As well, MJN110, but not AM251, infusions into the interoceptive insular cortex (a region known to be activated in acute MWD) also prevented the establishment of the place aversion by a CB1 mechanism of action. These findings reveal the respective sites of action of systemically administered MJN110 and AM251 in regulating the aversive effects of MWD.

Indexed as

AmygdalaAnalysis of VarianceAnimalsArachidonic AcidsCannabinoid Receptor AgonistsCarbamatesCerebral CortexConditioning, OperantDisease Models, AnimalDose-Response Relationship, DrugDrug Administration RoutesEndocannabinoidsGlyceridesMaleMonoacylglycerol LipasesMorphineArachidonic AcidsCannabinoid Receptor AgonistsCarbamatesEndocannabinoidsGlyceridesglyceryl 2-arachidonateMJN110Monoacylglycerol LipasesMorphineNaloxoneNarcotic AntagonistsNarcoticsSuccinimides

Identifiers

PMID26647976
PMCPMC4869055
OpenAlexW2193535549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.